One area of broad interest in biomedicine is the prevention of infectious disease, with a major focus on the development of vaccines against many viruses1

One area of broad interest in biomedicine is the prevention of infectious disease, with a major focus on the development of vaccines against many viruses1. foreign molecules or antigens and are useful in a variety of applications. One area of broad interest in biomedicine is the prevention of infectious disease, with a major focus on the development of vaccines against many viruses1. One of the viruses for which we still lack universal vaccines is the human immunodeficiency virus (HIV), which causes acquired immune deficiency syndrome (AIDS); it is already responsible for more than 35 million deaths worldwide24. Although many researchers are making great efforts58, the development of HIV vaccines has been hindered by the high mutation rate of HIV genomes, leading to rapid drug resistance2. The role of vaccines is usually to induce antibodies that have desired functions, such as neutralizing activities, and a vaccine is usually often made from weakened or killed forms of the microbe. To develop an effective vaccine against HIV, the elicitation of broadly neutralizing antibodies against the conserved vulnerable sites on the surface envelope glycoproteins, gp120 and gp41, is usually required9. Toward this ambitious goal, understanding the relationships between the antibody structure, function, and dynamics is essential. In antibodies, the antigen binding site consists of 6 hypervariable loops, which are also known as complementarity determining regions (CDRs). The specificities of antibodies are governed by the variety of these loop sequences and conformations. Among the 6 CDRs, CDR-H3 is the most diverse in terms of both sequence and structure1012. Accumulating structural information has enabled the classification of 5 of the CDRs (L1, L2, L3, H1, and H2) into the limited number of so-called canonical structures1317; however, the structural classification of the entire CDR-H3 has not yet been feasible18. Furthermore, while the lengths of the non-H3 CDRs are limited, those of the CDR-H3 significantly vary, from 3- to 34-residues with an average length of 13.5 for human antibodies19(Kabat/Chothia definition). Numerous GGTI298 Trifluoroacetate reports have delineated the structural basis of the neutralizing activities of antibodies against HIV20. Among the neutralizing antibodies, PG16 was discovered to have the ability to neutralize ~80% of HIV isolates, by binding to novel epitopes preferentially expressed on the surface envelope glycoprotein21. Recently, the crystal structure of PG16 was decided at 2.4 resolution, and revealed that PG16 possesses an unexpectedly long CDR-H3 consisting of 28 residues (Kabat/Chothia definition)22(Fig.1). GGTI298 Trifluoroacetate The CDR-H3 protrudes from the GGTI298 Trifluoroacetate variable domain, and this protruded portion was referred to as a hammerhead. The C-terminal region of the CDR-H3 has a common kinked conformation15,23and is usually supported by several contacts between the variable domains of the light and heavy chains (light variable domain (VLdomain) and the non-CDR-H3 heavy variable domain name (non-CDR-H3 VHdomain)), as shown in Fig.1. == Physique 1. == Structure of PG16 used in the simulations (PDB ID: 4DQO). CDR-H3 is usually colored red and orange (the specificity loop), the other VHdomain (non-CDR-H3 VHdomain) is usually purple, and the VLdomain TSPAN33 is usually pink. TyrH100Qis usually shown as a stick model. To highlight the relationship between the GGTI298 Trifluoroacetate position of TyrH100Qand the antigen, the antigen molecule is usually represented as a gray cartoon model, but it was not included in the simulations. Despite the structural diversity of the CDR-H3s in antibodies in general10, based on the crystal structures of the antigen-bound and unbound says22,24, PG16 did not undergo a large conformational change upon antigen binding. The hammerhead structure.